ADARx Pharmaceuticals (NASDAQ:ADRX) Director Buys 950,000 Shares of Company Stock

ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) Director Carl Gordon bought 950,000 shares of the business’s stock in a transaction that occurred on Monday, September 28th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $16,150,000.00. Following the completion of the purchase, the director owned 14,325,529 shares in the company, valued at $243,533,993. This trade represents a 7.10% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

ADARx Pharmaceuticals Price Performance

ADRX stock traded down $0.70 during midday trading on Wednesday, hitting $19.94. The company’s stock had a trading volume of 788,778 shares, compared to its average volume of 1,097,539. ADARx Pharmaceuticals, Inc. has a 52-week low of $18.50 and a 52-week high of $23.21.

About ADARx Pharmaceuticals

ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing RNA-based medicines for immune-mediated and other serious diseases. The company is headquartered in San Diego, California, and uses proprietary technologies designed to modulate disease-related proteins at the RNA level.

ADARx’s pipeline includes investigational therapies intended to address conditions involving the complement system, coagulation pathways and other biologic mechanisms. Its programs are designed to provide targeted, durable treatment through approaches such as RNA interference and related forms of RNA-based therapeutic intervention.

Founded in 2018, ADARx has advanced its drug candidates through preclinical and clinical development and has pursued regulatory and clinical activities in the United States and other international markets.